2011
Hunting in the rainforest and mayaro virus infection: An emerging alphavirus in Ecuador
Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH. Hunting in the rainforest and mayaro virus infection: An emerging alphavirus in Ecuador. Journal Of Global Infectious Diseases 2011, 3: 317-323. PMID: 22223990, PMCID: PMC3249982, DOI: 10.4103/0974-777x.91049.Peer-Reviewed Original ResearchMayaro virus infectionVirus infectionRisk factorsMayaro virusHumoral immune responsePotential risk factorsCross-sectional studyIgG-specific antibodiesSeroepidemiological methodsImmune responseStudy populationPrevalence ratesBirth cohortInfectionSporadic outbreaksSignificant predictorsVirusAlphavirusesArthropod vectorsEthnic groupsAmazonian nativesPotential presenceSubjectsNative menSystematic evaluation
2009
Assessing yellow fever risk in the Ecuadorian Amazon
Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH. Assessing yellow fever risk in the Ecuadorian Amazon. Journal Of Global Infectious Diseases 2009, 1: 7-13. PMID: 20300380, PMCID: PMC2840941, DOI: 10.4103/0974-777x.49188.Peer-Reviewed Original ResearchYellow fever casesYellow fever infectionFever infectionFever casesSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvicHumoral immune responseCross-sectional studyDengue-2 infectionsIgG-specific antibodiesGlutamic oxaloacetic transaminaseYellow fever outbreaksYellow fever riskMilitary personnelSeroepidemiological methodsClinical symptomsRisk factorsImmune responseOxaloacetic transaminaseGlutamic pyruvicFever riskFever outbreakAttack rateSpecific antibodiesYellow feverAnamnestic immune response to dengue and decreased severity of yellow fever
Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH. Anamnestic immune response to dengue and decreased severity of yellow fever. Journal Of Global Infectious Diseases 2009, 1: 111-116. PMID: 20300401, PMCID: PMC2840959, DOI: 10.4103/0974-777x.56257.Peer-Reviewed Original ResearchYellow fever infectionAnamnestic immune responseFever infectionDengue antibodiesImmune responseProtective immunityYellow feverDengue type 2 virusYellow fever casesHumoral immune responseCross-sectional studyDengue-2 infectionsPresence of antibodiesIgG-specific antibodiesCross-reactive antibodiesType 2 virusSeroepidemiological methodsLog-linear regression analysisDengue immunityDengue infectionSevere diseaseStudy populationFever casesSeroepidemiological surveyFever
2007
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine
H BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, Zulu I, Kankasa C, Wilfert C, Weidle PJ, Vermund SH, Stringer J. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007, 21: 957-964. PMID: 17457089, PMCID: PMC2745970, DOI: 10.1097/qad.0b013e32810996b2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountDrug Administration ScheduleEpidemiologic MethodsFemaleHIV InfectionsHumansInfectious Disease Transmission, VerticalNevirapinePregnancyPregnancy Complications, InfectiousReverse Transcriptase InhibitorsTreatment FailureTreatment OutcomeConceptsSingle-dose nevirapineClinical treatment failureCD4 cell responseAntiretroviral therapyTreatment failureNVP exposureTreatment outcomesCell responsesShort-term treatment outcomesPrior exposureChild HIV transmissionPrevention of motherCD4 cell changesPoor treatment outcomesNon-nucleoside reverseSignificant differencesWorld Health Organization guidelinesHealth Organization guidelinesART initiationCohort evaluationMultivariable analysisHIV transmissionHIV treatmentRisk factorsImmune response
2005
Treatment of Intestinal Helminths Does Not Reduce Plasma Concentrations of HIV-1 RNA in Coinfected Zambian Adults
Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, Bentwich Z, Vermund SH. Treatment of Intestinal Helminths Does Not Reduce Plasma Concentrations of HIV-1 RNA in Coinfected Zambian Adults. The Journal Of Infectious Diseases 2005, 192: 1277-1283. PMID: 16136473, PMCID: PMC2730764, DOI: 10.1086/444543.Peer-Reviewed Original ResearchConceptsHIV-1 RNAViral loadPlasma concentrationsAntihelminthic treatmentCopies/Helminth infectionsIntestinal helminthsHigh pretreatment viral loadMedian baseline viral loadPretreatment viral loadBaseline viral loadDysfunctional immune responseIntestinal helminth infectionsHuman immunodeficiency virusMean viral loadCopies/mLHigher helminth burdensPosttreatment visitAsymptomatic adultsImmunodeficiency virusProspective studyZambian adultsUninfected groupHIV-1Immune response
1998
Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection
1994
NIH conference. HIV vaccine development: a progress report.
Hoth DF, Bolognesi DP, Corey L, Vermund SH. NIH conference. HIV vaccine development: a progress report. Annals Of Internal Medicine 1994, 121: 603-11. PMID: 8085693, DOI: 10.7326/0003-4819-121-8-199410150-00008.Peer-Reviewed Original ResearchConceptsVaccine candidatesAnimal modelsHuman immunodeficiency virus (HIV) infectionCytotoxic T cell responsesLarge-scale efficacy trialsInnovative vaccine candidatesImmunodeficiency virus infectionT cell responsesCorrelates of immunityEffective preventive vaccineProtective immune responseDiversity of HIVHIV vaccine researchHuman phase IPromising vaccine candidateUseful animal modelPreventive vaccineEfficacy trialsVirus infectionImmune responseVaccine researchSuch trialsPhase ITrialsHIV